Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Closes $9M Public Offering of Stock

NEW YORK (GenomeWeb) – Signal Genetics announced today the closing of the public offering of its common shares, raising $9 million in gross proceeds. 

The Carlsbad, Calif.-based molecular diagnostics firm offered 3,214,285 shares of its stock at $2.80 per share and has granted the offering's underwriters a 45-day overallotment option to purchase up to 482,142 shares of its common stock. Aegis Capital and Chardan Capital Markets are the joint book-running managers on the offering.

Signal said last week when it priced the offering that proceeds will go toward the clinical development of new products and services, expansion of the company's commercialization efforts, working capital, and general corporate purposes. 

Signal's shares were up by almost 6 percent to $2.72 on the Nasdaq in afternoon trading on Monday.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.